Pancreatic Cancer Research

ResearcherThe University of Texas at AustinActive in the last 2 years

Kyaw Lwin Aung

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9889-0379; OpenAlex author ID A5066902945. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
53
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 3 papers · 2026: 3 papers

Papers 12

  1. Quiescent tumor cells shape the immunosuppressive microenvironment in pancreatic cancer. Co-author DOI 10.1038/s41467-026-75883-z↗
  2. Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2505783↗
  3. Pancreatic Cancer Cachexia: Integrating Mechanistic Insights With Clinical Management. Last author DOI 10.1200/op-26-00673↗
  4. Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. Co-author DOI 10.1038/s41467-025-60808-z↗
  5. The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. Co-author DOI 10.1038/s41698-025-00888-8↗
  6. ctDNA in Pancreatic Adenocarcinoma: A Critical Appraisal. Last author DOI 10.3390/curroncol32110589↗
  7. Impact of an Inter-Professional Clinic on Pancreatic Cancer Outcomes: A Retrospective Cohort Study. Co-author DOI 10.3390/curroncol31050194↗
  8. Primary ambulatory thromboprophylaxis in patients with pancreatic cancer receiving chemotherapy: hope or hype? Co-author DOI 10.1007/s00520-022-07138-8↗
  9. A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/jgo-22-86↗
  10. The Clinical Applicability of Primary Thromboprophylaxis in Ambulatory Patients With Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001799↗
  11. Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Co-author DOI 10.1158/1078-0432.ccr-17-2994↗
  12. Metformin for pancreatic cancer. Co-author DOI 10.1016/s1470-2045(15)00029-7↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jennifer Jane Knox · 5 shared papers, 2018–2025 · strength 0.66
  2. Steve Gallinger · 5 shared papers, 2018–2025 · strength 0.66
  3. Malcolm J. Moore · 5 shared papers, 2015–2025 · strength 0.65
  4. Sandra Elisabeth Fischer · 4 shared papers, 2018–2025 · strength 0.50
  5. Raymond Jang · 3 shared papers, 2024–2025 · strength 0.49
  6. Bryan McClellan · 1 shared paper, 2026 · strength 0.43
  7. William H. Matsui · 1 shared paper, 2026 · strength 0.43
  8. Thein Hlaing Oo · 2 shared papers, 2021–2022 · strength 0.40
  9. Spring Holter · 3 shared papers, 2018–2025 · strength 0.38
  10. Robert C. Grant · 3 shared papers, 2018–2025 · strength 0.38
  11. Grainne Mary O'Kane · 3 shared papers, 2018–2025 · strength 0.38
  12. Faiyaz Notta · 3 shared papers, 2018–2025 · strength 0.38
  13. Sujata Ojha · 1 shared paper, 2025 · strength 0.37
  14. Lyndon G Huang · 1 shared paper, 2026 · strength 0.36
  15. Sarbajit Mukherjee · 1 shared paper, 2026 · strength 0.36
  16. Neesha C. Dhani · 3 shared papers, 2018–2024 · strength 0.33
  17. Michelle Chan‐Seng‐Yue · 2 shared papers, 2025 · strength 0.33
  18. Erica S. Tsang · 2 shared papers, 2025 · strength 0.33
  19. George Zogopoulos · 2 shared papers, 2025 · strength 0.33
  20. Rachel Anne Goodwin · 2 shared papers, 2022–2025 · strength 0.29
  21. Alexander Starodub · 1 shared paper, 2026 · strength 0.23
  22. Wungki Park · 1 shared paper, 2026 · strength 0.23
  23. Joel Randolph Hecht · 1 shared paper, 2026 · strength 0.23
  24. Nilofer Saba Azad · 1 shared paper, 2026 · strength 0.23
  25. Brian Matthew Wolpin · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.